CardioFocus Acquires Electrophysiology Division from Galvanize Therapeutics

CardioFocus has acquired Galvanize Therapeutics’ Electrophysiology Technology division, including the CENTAURI System pulsed electric field generator which is CE marked and commercially available in the EU and the UK, and the QuickShot™ catheter ablation system, which is currently in development.

The acquisition also includes a broad intellectual property portfolio, including a licence to several basic patent families covering pulsed electric field therapies, ownership of several electrophysiology and pulsed field patent families, and unique knowledge of the proprietary waveform and algorithms to minimize microbubbles and muscle stimulation.

CardioFocus now has a full suite of differentiated and complementary ablation technologies, including the flagship HeartLight X3® catheter ablation technology for controlled and durable pulmonary vein isolation and the HeartLight X4, a pulsed field ablation balloon for true single-shot pulmonary vein isolation, which is expected to enter human trials in 2024.

This acquisition will expand our presence in Europe and the UK while supporting and growing our global HeartLight X3 and Centauri customer bases,” said Steve Ogilvie, CEO of CardioFocus.

en_GBEnglish (UK)